



## VICH Impact and future expectations

### Programme

June 23, 2010

4:00 – 7:00 PM **Registration Open**  
6:00 PM **Welcome Reception**

#### DAY 1 (June 24, 2010)

8:00 AM – 4:00 PM **Registration Open**

9:00 AM **Plenary Session I:**

**Official Opening Session**

*Chair: Bernard Vallat, Director of OIE*

**Introductory Remarks**

*Martin Terberger, European Commission*

09:25 AM **VICH – where are we?**

- **VICH Phase I and II: strategy and achievements**

*Hervé Marion VICH secretariat*

9:45 AM **Keynote Addresses: The needs and expectations of regulatory authorities outside the VICH regions**

*Mr. Issoufou Dare (UEMOA) West Africa Region*

*Representative of the Ministry of Agriculture, People's Republic of China*

*Dr. Marcos Vinicius de S. Lendro, MAPA, Brazil*

10:30 AM **Keynote Address: The needs and expectations of a global industry**

*Mr. Eric Maree (Virbac), IFAH Board president*

10:50 AM **Questions**

11:00 AM **Coffee break**

11:30 AM – 17:00 PM **Workshops and Poster session**

Three workshops (two from 'stream 1' and one from 'stream 2') and a poster session will run in parallel; there will be three sessions each of one hour duration, separated by a lunch break and an afternoon tea/coffee break. Each of the nine workshops will be run by a chairperson who will be assisted by a rapporteur. The conclusions of the workshops will be presented to the plenary session on day 2 of the conference.

For more details on the workshops please see the next page.

### **Workshops Stream 1: Impact of VICH guidelines and future topics**

*Review and discussion of guidelines adopted, scientific issues, impact of the guidelines locally and globally, new topics, future vision with members of the expert working groups (EWGs).*

**Session 1:** (a) EWG on Safety (toxicology) and EWG on Target Animal Safety (TAS) (Pharmaceuticals); plus: Implementing the “3Rs” (welfare of experimental animals)  
(b) EWG on Pharmacovigilance

**Session 2:** (a) EWG on Metabolism and Residue Kinetics  
(b) EWG on Biological quality monitoring and EWG on TAS (Biologicals)

**Session 3:** (a) EWG on Microbiological ADI (acceptable daily intake of residues)  
(b) EWGs on Quality, Efficacy, and Environmental Risk Assessment

### **Workshops Stream 2: VICH as a global partner**

*The needs and expectations of regulatory authorities in non-VICH regions; the needs and expectations of industry, VICH outreach, vision for the future.*

#### **Session 1: Global environment for veterinary medicines**

- OIE Strategy and role in animal health
- Role of CODEX and JECFA
- Role of VICH
- Discussion

#### **Session 2: Plans for VICH Global Outreach**

- The results of the OIE/VICH survey
- Needs of non-VICH countries
- Proposal for VICH Global Outreach – new topics from non-VICH countries, information sharing, communication, training, assistance in implementation.
- Discussion

#### **Session 3: Value and Future Vision (VICH Phase III)**

- What value does VICH bring (to industry / regulators / animal health / other)?
- What are the future objectives and needs?
- Which aspects of the VICH mandate should be changed to accommodate future needs?
- Which key elements require consideration in the phase III strategy?

### **Poster session**

**Session 1:** with experts present from:

- - Metabolism and Residue Kinetics
- - Quality
- - Efficacy (anthelmintics)

**Session 2:** with experts present from:

- - Safety
- - Environmental safety
- - Microbiological ADI

**Session 3:** with experts present from:

- - Pharmacovigilance
- - Biological Quality Monitoring
- - ECVAM/ICVAM/JCVAM

**5:00 PM**      **Adjourn for the day**

**6:00 PM**      **Gala dinner (Meeting at 6:00 PM at the dinner venue)**

**DAY 2 (June 25, 2010)**

**(7:30 AM – 4:00 PM Day 2 Registration)**

**08:30 AM Plenary Session II: Reports from Stream 1 Workshops on “Impact, value, key areas of scientific debate, and future topics”**

*Chair: Tadashi Nagata, JVPA*

- EWG on Biological topics
- EWG on Microbiological ADI
- EWG on Safety
- EWG on METRES
- EWG on Pharmacovigilance
- EWGs on Quality, Efficacy and EIA

**10:00 Panel discussion**

**10:30 AM Coffee break**

**11:00 AM Plenary Session III: Reports from Stream 2 Workshops**

*Chair: Monique Elbit, Deputy Director General OIE*

- Session 1 (*rapporteur*)
- Session 2 (*rapporteur*)
- Session 3 (*rapporteur*)
- Summary Presentation from OIE, Patrick Dehaumont, OIE

**Panel discussion**

**12:30 PM Lunch**

**2:00 PM Plenary Session IV: Benefits and Impact of the VICH Initiative; and spreading the word**

*Chair: Bernadette Dunham, FDA*

*Panel: a member of each VICH region, plus India, China, Brazil, AAHA*

Panel discussion with representatives from the regulatory agencies and industry from the participating regions and observer nations and Non-VICH countries; to discuss the benefits and impact of the VICH initiative, and how to spread the word to other countries so that VICH guidelines are recognised, or products authorised in VICH regions.

**3:20 PM Coffee Break**

**3:50 PM Plenary Session V: VICH – The Vision for the Future**

*Chair: Barbara Freischem, IFAH Executive Director*

**The Progress of ICH, Michelle Limoli, FDA**

**How can VICH be inspired from the evolutions in ICH? Martin Terberger, European Commission**

**VICH Phase III future opportunities, Ludwig Klostermann, IFAH-Europe**

**4:50 PM Conclusion of Conference, David Mackay, EMEA**

**5:00 PM Closure of the Conference**